Fig. 3.
Predictability of MGMT promoter methylation status (unmethylated vs methylated) in newly diagnosed untreated glioma patients. (A, B) None of the investigated CEST contrasts allowed for significant prediction of the MGMT promoter methylation in glioma patients. Two GBM patients with unmethylated (GBM MGMT−: c1–g1) and methylated (GBM MGMT+: c2–g2) promoter shown: ci: GdCE T1-w, di: T2-w (TSE), relaxation-compensated multipool CEST MRI at 7T with separated APT (ei), NOE (fi), and dns-APT (gi) effects (unit: %). A tendency toward higher signal intensities for patients with unmethylated MGMT promoter was observed for all investigated CEST contrasts.